Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-290 maintenance therapy versus placebo in platinum-sensitive recurrent ovarian cancer
ChiCTR1800014643Phase 3Recruiting
- Sponsor
- BeiGene
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing BGB-290 maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Dec 2017; status: recruiting.
02
Drugs
pamiparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR1800014643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014643.